PKCθ (protein kinase Cθ) is a central signalling molecule in the T-cell receptor activation pathway and is a target for treatment of a number of diseases. Several PKC inhibitors are in the drug-discovery pharmaceutical programmes today for the treatment of cancer, diabetes and arthritis. CD4 + T-lymphocytes also play a critical role in the initiation and progression of allergic airway inflammation. Our goal is the development of PKCθ antagonists as a means to control asthma and autoimmune diseases, using the strategy based on developing small-molecule agents that would block the enzyme's catalytic activity. Here, we discuss our work on the discovery of lead chemical series and review our X-ray structural and modelling approaches, including a structure-surrogate strategy that helped guide us in the lead compound optimizations.
Introduction
PKCθ (protein kinase Cθ), a Ca 2+ -independent novel PKC subfamily member, is a key TCR (T-cell receptor) signalling molecule [1, 2] . PKCθ -deficient mice have a defect in T-cell activation and IL-2 (interleukin-2) production, but not in T-cell development or T-effector functions in viral clearance [3, 4] . PKCθ regulates pulmonary inflammation and airway hyper-responsiveness in a Th2-dependent manner [5, 6] , and regulates T-cells in experimental autoimmune encephalomyelitis [7, 8] , arthritis [9] and colitis [8] . Together with these and other lines of supporting evidence, we have proposed that selective PKCθ inhibition may allow for therapeutic modulation of T-cell-mediated diseases [10] . PKCθ signalling may play a role in IgE cross-linking-induced effector function in mast cells [11] , and may contribute in part to IgE-dependent immediate hypersensitivity. PKCθ has also been reported to contribute in part to mast cell adhesion [12] . Mast cells are important contributors in bronchoconstriction and lung inflammation [13] ; thus a selective PKCθ inhibitor may target both mast cell and T-cell activation in the asthma.
In addition to T-cells and mast cells, PKCθ is also expressed in skeletal muscle, with a role in regulating IRS-1 (insulin receptor substrate-1) signalling and insulin resistance [14, 15] . PKCθ is also expressed in ICC (interstitial cells of Cajal), which transduce neural inputs in the gut [16] . PKCθ activity is reported in intestinal epithelial barrier function and neuromuscular contractility [17] . Lastly, PKCθ as a GIST (gastrointestinal stromal tumour) marker suggests that PKCθ signalling may be a potential targeting mechanism for regulating KIT-negative tumours [18, 19] .
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T-cell signalling involving PKCθ in response to costimulation scenarios has been studied extensively [20, 21] and is reviewed elsewhere [10] . In the present review, we will focus on strategies relevant to screening, optimization and evaluation of a PKCθ inhibitor. Structure-based optimization of inhibitor structures will be discussed in the context of challenges in developing a selective kinase inhibitor.
Paradigm for identification of PKCθ inhibitor leads
Early efforts in determining mode of binding to the ATPbinding site are important for the generation of potent and selective inhibitors. With this in mind, we initiated early in the programme the design and production of various expression constructs of human PCKθ , both with respect to construct boundaries and amino acid residue point mutations to facilitate crystallization. This effort led to the identification of the two PKCθ kinase domain Escherichia coli expression constructs, which displayed high catalytic activity and favourable solution properties upon purification: PKCθ 362−706 (residues 362-706) and PKCθ 352(C357S)706 in which Cys 357 was mutated to serine (residues 352-706). Both proteins were purified to homogeneity and screened using a wide variety of crystallization conditions (approx. 1000 unique conditions each). Crystallization screening was facilitated by a liquidhandling robot (Hamilton) and a nanopipetting hanging drop robot (Cartesian Technologies), and crystallization images were captured using a crystal storage and imaging system (Formulatrix). While screens with the longer PKCθ from ammonium sulfate conditions and with significantly enhanced diffraction quality, ultimately resulting in the atomic 2.0 Å resolution elucidation of the PKCθ catalytic domain [22] .
The PKCθ catalytic domain has been characterized for enzyme kinetics [22, 23] . These studies reveal the kinetic mechanism and structural features describing a highly active kinase molecule that is optimal for an activity-based screen for inhibitors. PKCθ kinase domain activity correlates with the ability of the protein to be autophosphorylated on the highly conserved activation loop Thr 538 . The catalytic domain has been analysed for phosphorylation sites, revealing an interdependence of activation loop Thr 538 and hydrophobic motif Ser 695 , the two sites identified in the staurosporinebound crystal structure. The hydrophobic motif S695A mutation abolishes both the Thr 538 activation loop autophosphorylation and PKCθ kinase activity. In addition, a key PKCθ N-terminal-regulatory domain autophosphorylation site Thr 219 has been described that does not regulate PKCθ kinase activity, but is important in mediating appropriate membrane translocation upon TCR stimulation [24] .
We have identified several reversible ATP competitive kinase inhibitors that are under optimization and evaluation. Inhibitor optimization focusing both on potency and on broad selectivity [e.g. Src tyrosine kinase and other AGCtype kinases (protein kinase A/protein kinase G/protein kinase C-family kinases)] early in the strategic paradigm is important in identifying leads for selective T-cell targeting ( Figure 1 ). In addition to potency and selectivity, prioritization of the physical properties early for characteristics such as solubility and structural novelty enables the identification of lead inhibitors worth pursuing for further optimization.
Structure-based strategies for evaluating PKCθ inhibitor-binding mode and selectivity
The crystal structural information for PKCθ bound to staurosporine was utilized for generating binding models for the representative PKCθ inhibitor compounds that broadly encompassed five advanced series. These efforts were assisted by docking studies and by molecular dynamic simulations. Attempts to crystallize advanced hit series with the original PKCθ 362−706 construct, and with specifically designed PKCθ mutants to promote different crystal packing, repeatedly led to the aforementioned needle-like crystal form that was suffering from diffraction limitations. We therefore decided to use the related and previously crystallized PDK1 (3-phosphoinositide-dependent protein kinase-1) kinase [25] as a structural mimic for co-crystallization with PKCθ inhibitors. The early usage of PDK1 as a substitute model for PKCθ was also inspired by the published crystal structures of PDK1 with bisindolylmaleimide-based nanomolar PKC inhibitors [26] . However, the compounds selected for their ability to inhibit the PDK1 kinase activity showed weak inhibition, with IC 50 greater than 20 µM. As one of our advanced series had features in common with the Rho-kinase-specific inhibitor Fasudil [PKCθ, IC 50 = 11 µM; PDK1, IC 50 = 160-320 µM; and PKA (protein kinase A), IC 50 = 1 µM], we decided to resolve the crystal structure of Fasudil with PDK1 to allow for a comparison with its characteristic binding to PKA [27] . We found that the binding mode of Fasudil to PDK1 was essentially identical with that reported with PKA; thus we concluded that the PDK1 structure-based approach is justified and possibly useful for modelling purposes and refinement recommendations. As with Fasudil, the co-crystals of PDK1 with other compounds were obtained through a crystal soaking protocol in which PDK1-bound p[NH]ppA molecules had been displaced with a compound of interest (compound concentration ∼ 10-20 mM and soaking time 3-4 days). Consequently, all subsequent models for the five lead series bound to PKCθ , with the key interactions and opportunities for synthesis, were derived from PDK1 structures of related analogues.
Through an iterative process of chemical synthesis, molecular modelling, biochemical testing and cell-based characterization, as Figure 1 illustrates, we have found highly potent nanomolar inhibitors among two of the five lead series that comprised the advanced hit compounds. Despite general consistency between the model predictions and actual compound performance, the existing binding models were capable of explaining some, but not all, of the SARs (structure-activity relationships) obtained. Specifically, the PKCθ-inhibitor binding models predicted a key interaction through the hinge region, Met 458 and Asp 522 , in which case the SAR around the headpiece of the Series 2 pharmacophore could not be explained. In addition, Series 2 compounds suffered from lack of selectivity over Src-family kinases. In an attempt to address these issues, we have co-crystallized our lead compounds with a member of the Src family of protein tyrosine kinases. These new co-structures, obtained both by soaking and co-crystallization, revealed different positioning of the headpiece in the ATP-binding pocket than was assumed from the PDK1 structure approaches. Specifically, as shown in Figure 2 , the headpiece occupying the so-called 'specificity pocket' was in a hydrogen bond with Glu 428 and not with Asp 522 as predicted before. This new binding mode necessitated revisiting the structure of the glycine-rich loop (P-loop) in PKCθ to avoid steric clashes between the P-loop and computationally modelled compounds. Thus the backbone conformation of the P-loop had to be remodelled from its inhibitory closed position, as was previously observed in the complex with staurosporine [17] , to a more open position as was now being observed with the Src kinase structures. Consequently, the SAR around the headpiece became well explained with this new 'hybrid' PKCθ model. The latter was further optimized using induced Fit docking with GLIDE (Schrödinger, Portland, OR, U.S.A.; 2002) and structure validation was performed using the docking software FLO [28] . In light of the information revealed by the above studies, re-docking and reassessment of the SARs for both lead series were made and new binding modes were predicted. The results from these structural efforts subsequently helped to identify compounds with improved selectivity (78-344-fold) against representative Srcfamily kinases.
Structural strategies for selectivity within the PKC family
Although several potent inhibitors were found to have good selectivity over a broad screening selectivity panel of targets, they were not very selective within the PKC family kinases. The closest relative of PKCθ within the PKC family kinases is PKCδ with the ATP-binding site of PKCδ differing from that of PKCθ by only a single amino acid residue (Tyr 460 to phenylalanine in PKCδ). To aid in the understanding of a possible source of selectivity for PKCθ inhibitors against PKCδ, we compared the sequence of PKCθ with PKCδ and PKA in the region of missing electron density in the PKCθ X-ray structure, residues 650-687. This region is ordered and close to the ATP-binding site in PKA [29] . Computational modelling of residues 650-668 in PKCθ using the published PKA structure (PDB accession codes 1STC and 1Q8W) was explored, with the hypothesis of deriving selective interactions in this region.
Among residues that differ between PKCθ and PKA in that region [Phe 659 (Arg), Cys 661 (Tyr) and Lys 666 (Gln)], modelling places residue Lys 666 close to the ATP-binding site, thus suggesting that it may be a possible explanation for the modest selectivity seen for some of the PKCθ inhibitor compounds and the reverse selectivity in favour of PKCδ seen for one compound from Series 2. In order to test the hypothesis that tail pieces with an acceptor/negative charge favour PKCθ through a possible interaction with Lys 666 and those with a donor/positive charge favour PKCδ, replacements for a solubilizing tail were proposed. In parallel, a modified scaffold that would present a solubilizing tail in a different fashion to the protein was evaluated.
Collectively, as shown in Figure 3 , these efforts helped improve selectivity against PKCδ severalfold, confirming the hypothesis that improved selectivity for both series may be achieved through interaction with the flexible loop that is unresolved in the PKCθ structure [22] . Some but not all of these molecules are selective against PKCε and PKCη, the remaining novel PKC subfamily members. These inhibitors are selective against the other two PKC subfamilies, conventional PKCs and atypical PKCs, in addition to being selective against several other kinase family representatives. Further characterization is ongoing to continue to improve selectivity for PKCθ inhibition.
Assessing cell-based selectivity of PKCθ inhibition
Beyond determining potency and selectivity of PKCθ inhibitor leads in enzymatic assays, the same must also be confirmed in cell-based functional assays. T-cell signalling involves several other kinase families including Src-family kinases and MAPKs (mitogen-activated protein kinases). T-cells from PKCθ -deficient mice have an attenuated response in T-cell co-stimulation-induced IL-2 production; however, the significantly lower IL-2 production is quantifiable and is thus likely to be a consequence of PKCθ-independent signalling pathways to some IL-2 gene expression [1, 2] . Indeed, T-cell proliferation defects that are observed upon antigen stimulation of T-cells from immunized PKCθ -deficient mice, do not mimic the lack of a proliferation response of T-cells from naïve mice ( [5] and L. Mosyak, Z.-B. Xu, D. Joseph-McCarthy, N. Brooijmans, W.S. Somers and D. Chaudhary, unpublished work). This also suggests that PKCθ-independent signalling is contributing to some T-cell proliferation. Thus T-cell IL-2 production assays using PKCθ -deficient T-cells render the evaluation possible for inhibitor effects on kinases that are independent of PKCθ activity. Other cell-based assays, such as LPS (lipopolysaccharide)-induced TNF (tumour necrosis factor) production and B-cell receptor signalling, also afford cellbased kinase selectivity platforms against various MAPKs and tyrosine kinases.
Concluding remarks
T-cell inhibition in vitro may be confirmed with inhibition of T-cell activation in vivo by anti-CD3 administrationinduced serum IL-2 levels in mice. Lead molecules are also characterized for pharmacokinetic parameters for appropriate profiles such as adequate exposure, distribution, clearance and stability. Preclinical models of efficacy include antigen-induced allergic lung inflammation and airway hyper-reactivity rodent models of asthma [6] , collageninduced arthritis models for rheumatic disease [9] and experimental autoimmune encephalomyelitis for multiple sclerosis [7] . To further enhance structure-guided lead optimization, we are currently pursuing a PKA-based surrogate approach, in which residues in the ATP-binding site of PKA are being mutated to their counterparts in PKCθ. Production, enzymatic characterization and use of different PKA-PKCθ chimaeras as a structural mimic are in progress. We have identified a PKCθ inhibitor that is potent and active in cell-based assays with reasonable selectivity and is efficacious in attenuating allergic lung inflammation. Further characterization and additional optimization efforts are ongoing in the search of a therapeutic candidate.
